Arsenic Trioxide vs Durvalumab

## Arsenic Trioxide vs Durvalumab: Overview

This comparison examines the pharmacological differences between **Arsenic Trioxide** and **Durvalumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Arsenic Trioxide — N/A; Durvalumab — 17 days.

## Chemical Properties

**Type**: Arsenic Trioxide — Small molecule; Durvalumab — Antibody.